Once-daily Insulin — Competitive Intelligence Brief

Once-daily Insulin (Once-daily Insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting insulin. Area: Diabetes.

marketed Long-acting insulin Insulin receptor Diabetes Small molecule

Target snapshot

Once-daily Insulin (Once-daily Insulin) — Hospital Universitario Dr. Jose E. Gonzalez. Once-daily insulin replaces or supplements the body's natural insulin production to regulate blood glucose levels by facilitating glucose uptake into cells and promoting glycogen synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Once-daily Insulin TARGET	Once-daily Insulin	Hospital Universitario Dr. Jose E. Gonzalez	marketed	Long-acting insulin	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting insulin class)

1. Ain Shams University · 1 drug in this class
2. Hospital Universitario Dr. Jose E. Gonzalez · 1 drug in this class
3. Sanofi · 1 drug in this class